# US 8,148,109 B2 · Interferon-like proteins and uses thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 8,148,109 B2 - Document ID: US8148109B2 - Status: Granted - Kind: B2 - Application number: 11/200,389 - Filed: 2005-08-08 - Published: 2006-02-02 - Granted: 2012-04-03 - Earliest claimed: 1999-12-08 - Assignees: Amgen Inc. - Inventors: Andrew Welcher; Duanzhi Wen; Michael Kelley - Web page: https://patentgrep.com/patent/US8148109B2 ## CPC - G01N 33/6866: {Interferon} - A61P 25/00: Drugs for disorders of the nervous system - A61P 37/02: Immunomodulators - C07K 14/555: Interferons [IFN] - A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic) - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy - C07K 2319/00: Fusion polypeptide - C07K 2319/02: containing a signal sequence - C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto - C12N 2799/021: for the expression of a heterologous nucleic acid - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) ## Abstract The present invention provides Interferon-Like (IFN-L) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing IFN-L polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with IFN-L polypeptides. ## Claims ### Claim 1 An isolated polypeptide comprising an amino acid sequence: (a) as set forth in SEQ ID NO: 5; or (b) encoded by the DNA insert in ATCC Deposit No. PTA-976. ### Claim 2 An isolated polypeptide comprising the amino acid sequence as set forth in SEQ ID NO: 6, optionally further comprising an amino-terminal methionine. ### Claim 3 An isolated polypeptide encoded by a nucleic acid molecule comprising a nucleotide sequence: (a) as set forth in SEQ ID NO: 4; (b) of the DNA insert in ATCC Deposit No. PTA-976; or (c) encoding a polypeptide as set forth in SEQ ID NO: 5. ### Claim 4 (depends on 1, 2) A composition comprising the polypeptide of any of claim 1, 2, or 3, and a pharmaceutically acceptable formulation agent. ### Claim 5 (depends on 4) The composition of claim 4, wherein the pharmaceutically acceptable formulation agent is a carrier, adjuvant, solubilizer, stabilizer, or anti-oxidant. ### Claim 6 (depends on 4) The composition of claim 4, wherein the polypeptide comprises the amino acid sequence as set forth in SEQ ID NO: 6. ### Claim 7 (depends on 1, 2) A polypeptide of any of claim 1, 2, or 3 that is covalently attached to a water soluble polymer. ### Claim 8 (depends on 7) The polypeptide of Claim 7, wherein the water-soluble polymer is polyethylene glycol, monomethoxy-polyethylene glycol, dextran, cellulose, poly-(N-vinyl pyrrolidone) polyethylene glycol, propylene glycol homopolymers, polypropylene oxidelethylene oxide copolymers, polyoxyethylated polyols, or polyvinyl alcohol. ### Claim 9 (depends on 1, 2) A fusion polypeptide comprising the polypeptide of any of claim 1, 2, or 3 fused to a heterologous amino acid sequence. ### Claim 10 (depends on 9) The fusion polypeptide of claim 9, wherein the heterologous amino acid sequence is an IgG constant domain or fragment thereof. ### Claim 11 A polypeptide produced by a process comprising culturing a host cell comprising a vector comprising a nucleic acid molecule comprising a nucleotide sequence: (a) as set forth in SEQ ID NO: 4; (b) of the DNA insert in ATCC Deposit No. PTA-976; or (c) encoding a polypeptide as set forth in SEQ ID NO: 5; under suitable conditions to express the polypeptide, and optionally isolating the polypeptide from the culture. ### Claim 12 (depends on 11) The polypeptide of claim 11, wherein the host cell is a eukaryotic cell. ### Claim 13 (depends on 11) The polypeptide of claim 11, wherein the host cell is a prokaryotic cell.